메뉴 건너뛰기




Volumn 27, Issue 3, 2008, Pages

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT;

EID: 44449114349     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.27.3.w185     Document Type: Article
Times cited : (83)

References (53)
  • 1
    • 34248586934 scopus 로고    scopus 로고
    • Medicaid's Prior Authorization Program and Access to Atypical Antipsychotic Medications
    • J.M. Polinski, P.S. Wang, and M.A. Fischer, "Medicaid's Prior Authorization Program and Access to Atypical Antipsychotic Medications," Health Affairs 26. no. 3 (2007): 750-760;
    • (2007) Health Affairs , vol.26 , Issue.3 , pp. 750-760
    • Polinski, J.M.1    Wang, P.S.2    Fischer, M.A.3
  • 2
    • 17244370794 scopus 로고    scopus 로고
    • Medicaid Policies to Contain Psychiatric Drug Costs
    • and C. Koyanagi, S. Forquer, and E. Alfano, "Medicaid Policies to Contain Psychiatric Drug Costs," Health Affairs 24, no. 2 (2005): 536-544.
    • (2005) Health Affairs , vol.24 , Issue.2 , pp. 536-544
    • Koyanagi, C.1    Forquer, S.2    Alfano, E.3
  • 3
    • 33947611154 scopus 로고    scopus 로고
    • Polinski et al, Medicaid's Prior Authorization Program; and H.A. Huskamp et al., Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D, Psychiatric Services 58, no. 3 (2007): 308-310.
    • Polinski et al, "Medicaid's Prior Authorization Program"; and H.A. Huskamp et al., "Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D," Psychiatric Services 58, no. 3 (2007): 308-310.
  • 5
    • 2942648152 scopus 로고    scopus 로고
    • Schizophrenia
    • K.T. Mueser and S.R. McGurk, "Schizophrenia," Lancet 363, no. 9426 (2004): 2063-2072,
    • (2004) Lancet , vol.363 , Issue.9426 , pp. 2063-2072
    • Mueser, K.T.1    McGurk, S.R.2
  • 6
    • 0142244688 scopus 로고    scopus 로고
    • and R. Freedman, Schizophrenia, New England Journal of Medicine 349, no. 18 (2003): 1738-1749.
    • and R. Freedman, "Schizophrenia," New England Journal of Medicine 349, no. 18 (2003): 1738-1749.
  • 7
    • 0035154103 scopus 로고    scopus 로고
    • Clinical Outcome Following Neuroleptic Discontinuation in Patients with Remitted Recent-Onset Schizophrenia
    • M. Gitlin et al., "Clinical Outcome Following Neuroleptic Discontinuation in Patients with Remitted Recent-Onset Schizophrenia," American Journal of Psychiatry 158, no. 11 (2001): 1835-1842.
    • (2001) American Journal of Psychiatry , vol.158 , Issue.11 , pp. 1835-1842
    • Gitlin, M.1
  • 8
    • 44449090754 scopus 로고    scopus 로고
    • Mueser and McGurk, Schizophrenia;
    • Mueser and McGurk, "Schizophrenia";
  • 9
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
    • J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no. 12 (2005): 1209-1223;
    • (2005) New England Journal of Medicine , vol.353 , Issue.12 , pp. 1209-1223
    • Lieberman, J.A.1
  • 11
    • 39549111228 scopus 로고    scopus 로고
    • A Longitudinal Study of Medication Non-Adherence and Hospitalization Risk in Schizophrenia
    • and M.R. Law et al., "A Longitudinal Study of Medication Non-Adherence and Hospitalization Risk in Schizophrenia," Journal of Clinical Psychiatry 69, no. 1 (2008): 47-53.
    • (2008) Journal of Clinical Psychiatry , vol.69 , Issue.1 , pp. 47-53
    • Law, M.R.1
  • 12
    • 44449177331 scopus 로고    scopus 로고
    • Mueser and McGurk, Schizophrenia;
    • Mueser and McGurk,, "Schizophrenia";
  • 13
    • 44449156935 scopus 로고    scopus 로고
    • Effectiveness of Antipsychotic
    • Lieberman et al., "Effectiveness of Antipsychotic Drugs";
    • Drugs
    • Lieberman1
  • 14
    • 0036886986 scopus 로고    scopus 로고
    • Safety and Tolerability: How Do Newer Generation 'Atypical' Antipsychotics Compare?
    • and R. Tandon, "Safety and Tolerability: How Do Newer Generation 'Atypical' Antipsychotics Compare?" Psychiatric Quarterly 73, no. 4 (2002): 297-311.
    • (2002) Psychiatric Quarterly , vol.73 , Issue.4 , pp. 297-311
    • Tandon, R.1
  • 15
    • 4344699183 scopus 로고    scopus 로고
    • Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid
    • S.B. Soumerai, "Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid," Health Affairs 23, no. 1 (2004): 135-146.
    • (2004) Health Affairs , vol.23 , Issue.1 , pp. 135-146
    • Soumerai, S.B.1
  • 16
    • 44449179553 scopus 로고    scopus 로고
    • National Alliance on Mental Illness Maine, accessed 1 February 2008
    • National Alliance on Mental Illness Maine, "Calls in Response to the 2003 Implementation of Limits on Access to MaineCare Medications," http://www.nami.org/Content/Microsites186/NAMI_Maine/Home174/Whats_New89/ NAMI_Maine_Monitered_Issues/RXaccess.pdf (accessed 1 February 2008).
    • Calls in Response to the 2003 Implementation of Limits on Access to MaineCare Medications
  • 17
    • 0028169466 scopus 로고
    • Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia
    • S.B. Soumerai et al., "Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia," New England Journal of Medicine 331, no. 10 (1994): 650-655.
    • (1994) New England Journal of Medicine , vol.331 , Issue.10 , pp. 650-655
    • Soumerai, S.B.1
  • 19
    • 0026719581 scopus 로고
    • Does Capitation Affect the Health of the Chronically Mentally Ill? Results from a Randomized Trial
    • and N. Lurie et al., "Does Capitation Affect the Health of the Chronically Mentally Ill? Results from a Randomized Trial," Journal of the American Medical Association 267, no. 24 (1992): 3300-3304.
    • (1992) Journal of the American Medical Association , vol.267 , Issue.24 , pp. 3300-3304
    • Lurie, N.1
  • 21
    • 44449156935 scopus 로고    scopus 로고
    • Effectiveness of Antipsychotic
    • Lieberman et al., "Effectiveness of Antipsychotic Drugs."
    • Drugs
    • Lieberman1
  • 22
    • 0035500992 scopus 로고    scopus 로고
    • Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies Using Claims Data
    • S. Schneeweiss et al., "Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies Using Claims Data," American Journal of Epidemiology 154, no. 9 (2001): 854-864.
    • (2001) American Journal of Epidemiology , vol.154 , Issue.9 , pp. 854-864
    • Schneeweiss, S.1
  • 24
    • 77957888445 scopus 로고
    • Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals
    • D. Lin, L. Wei, and Z. Ying, "Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals," Biometrika 80, no. 3 (1993): 557-572.
    • (1993) Biometrika , vol.80 , Issue.3 , pp. 557-572
    • Lin, D.1    Wei, L.2    Ying, Z.3
  • 26
    • 0036359656 scopus 로고    scopus 로고
    • Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research
    • and A.K. Wagner et al., "Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research," Journal of Clinical Pharmacy and Therapeutics 27, no. 4 (2002): 299-309.
    • (2002) Journal of Clinical Pharmacy and Therapeutics , vol.27 , Issue.4 , pp. 299-309
    • Wagner, A.K.1
  • 28
    • 44449173260 scopus 로고    scopus 로고
    • For more details regarding the effects of the policy on medication use, see the online appendix at
    • For more details regarding the effects of the policy on medication use, see the online appendix at http://content.healthaffairs.org/cgi/content/full/ hlthaff.27.3.185/DC2.
  • 29
    • 44449115406 scopus 로고    scopus 로고
    • See Exhibit A2 in the online appendix; ibid.
    • See Exhibit A2 in the online appendix; ibid.
  • 30
    • 3543124260 scopus 로고    scopus 로고
    • Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients with Schizophrenia
    • P.J. Weiden et al., "Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients with Schizophrenia," Psychiatric Services 55, no. 8 (2004): 886-891;
    • (2004) Psychiatric Services , vol.55 , Issue.8 , pp. 886-891
    • Weiden, P.J.1
  • 33
    • 4444242571 scopus 로고    scopus 로고
    • Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
    • D.L. Leslie and R.A. Rosenheck, "Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications," American Journal of Psychiatry 161, no. 9 (2004): 1709-1711.
    • (2004) American Journal of Psychiatry , vol.161 , Issue.9 , pp. 1709-1711
    • Leslie, D.L.1    Rosenheck, R.A.2
  • 35
    • 0037734369 scopus 로고    scopus 로고
    • Effect of a Mental Health 'Carve-Out' Program on the Continuity of Antipsychotic Therapy
    • and W.A. Ray, J.R. Daugherty, and K.G. Meador, "Effect of a Mental Health 'Carve-Out' Program on the Continuity of Antipsychotic Therapy," New England Journal of Medicine 348, no. 19 (2003): 1885-1894.
    • (2003) New England Journal of Medicine , vol.348 , Issue.19 , pp. 1885-1894
    • Ray, W.A.1    Daugherty, J.R.2    Meador, K.G.3
  • 39
    • 44449139221 scopus 로고    scopus 로고
    • State of Maine, Department of Health and Human Services, Office of Maine Care Services, Version, accessed 6 March
    • State of Maine, Department of Health and Human Services, Office of Maine Care Services, "MaineCare PDL with Criteria (07.01.07), PDF Version," http://www.mainecarepdl.org/index.pl/pdlfiles/mainecarepdl/copy-of-ssdc- pdl_maine-6_25_07-without-criteria2.pdf (accessed 6 March 2008);
    • (2008) MaineCare PDL with Criteria (07.01.07), PDF
  • 40
    • 44449132909 scopus 로고    scopus 로고
    • Version, accessed 6 March
    • and "MaineCare PDL (MEDEL Combined) with Criteria (01.31.08), PDF Version," http://www.mainecarepdl.org/index.pl/index7.pl/pdlfiles/ mainecare-pdl/ssdc-pdl_maine-1_1_08-with-criteria.pdf (accessed 6 March 2008).
    • (2008) MaineCare PDL (MEDEL Combined) with Criteria (01.31.08), PDF
  • 41
    • 44449137216 scopus 로고    scopus 로고
    • Spring, accessed 24 March 2008
    • MaineCare, "Pharmacy Benefit Update," Spring 2007, http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings (accessed 24 March 2008).
    • (2007) Pharmacy Benefit Update
    • MaineCare1
  • 42
    • 44449160141 scopus 로고    scopus 로고
    • Medicare Modernization Act
    • accessed 1 February 2008
    • Centers for Medicare and Medicaid Services, "Medicare Modernization Act: 2007 Final Guidelines - Formularies," 2007 http://www.cms.hhs.gov/ PrescriptionDrugCovContra/Downloads/CY07FormularyGuidance.pdf (accessed 1 February 2008).
    • (2007) Final Guidelines - Formularies
  • 43
    • 0347257056 scopus 로고    scopus 로고
    • Managing Psychotropic Drug Costs: Will Formularies Work?
    • H.A. Huskamp, "Managing Psychotropic Drug Costs: Will Formularies Work?" Health Affairs 22, no. 5 (2003): 84-96;
    • (2003) Health Affairs , vol.22 , Issue.5 , pp. 84-96
    • Huskamp, H.A.1
  • 44
    • 44449090753 scopus 로고    scopus 로고
    • Lieberman et al, Effectiveness of Antipsychotic Drugs; and Soumerai, Benefits and Risks of Increasing Restrictions.
    • Lieberman et al, "Effectiveness of Antipsychotic Drugs"; and Soumerai, "Benefits and Risks of Increasing Restrictions."
  • 45
    • 44449160653 scopus 로고    scopus 로고
    • MaineCare Advisory Committee's Prior Authorization Subcommittee Report and Recommendations on Prior Authorization for Prescription Drugs in the MaineCare and Drugs for the Elderly Programs, submitted to the Maine Department of Health and Human Services, Augusta, Maine, 19 January
    • MaineCare Advisory Committee's Prior Authorization Subcommittee Report and Recommendations on Prior Authorization for Prescription Drugs in the MaineCare and Drugs for the Elderly Programs, submitted to the Maine Department of Health and Human Services, Augusta, Maine, 19 January 2005.
    • (2005)
  • 46
    • 34249299424 scopus 로고    scopus 로고
    • Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First Four Months of the Medicare Prescription Drug Benefit
    • J.C. West et al., "Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First Four Months of the Medicare Prescription Drug Benefit," American Journal of Psychiatry 164, no. 5 (2007): 789-796.
    • (2007) American Journal of Psychiatry , vol.164 , Issue.5 , pp. 789-796
    • West, J.C.1
  • 47
    • 35148876967 scopus 로고    scopus 로고
    • P. Neuman et al., Medicare Prescription Drug Benefit Progress Report: Findings from a 2006 National Survey of Seniors, Health Affairs 26, no. 5 (2007): w630-w643 (published online 21 August 2007; 10.1377/hlthaff.26.5.w630).
    • P. Neuman et al., "Medicare Prescription Drug Benefit Progress Report: Findings from a 2006 National Survey of Seniors," Health Affairs 26, no. 5 (2007): w630-w643 (published online 21 August 2007; 10.1377/hlthaff.26.5.w630).
  • 48
    • 0029075682 scopus 로고
    • Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Anti-Inflammatory Drugs by Medicaid Patients
    • W.E. Smalley et al., "Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Anti-Inflammatory Drugs by Medicaid Patients," New England Journal of Medicine 332, no. 24 (1995): 1612-1617;
    • (1995) New England Journal of Medicine , vol.332 , Issue.24 , pp. 1612-1617
    • Smalley, W.E.1
  • 49
    • 0037076037 scopus 로고    scopus 로고
    • Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors
    • and S. Schneeweiss et al., "Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors," New England Journal of Medicine 346, no. 11 (2002): 822-829.
    • (2002) New England Journal of Medicine , vol.346 , Issue.11 , pp. 822-829
    • Schneeweiss, S.1
  • 53
    • 44449123347 scopus 로고    scopus 로고
    • CMS, Center for Medicaid and State Operations, Guidance for States on Preferred Drug Lists (PDLs) and Prior Authorization, State Medicaid Director Letter, 9 September 2004, SMDL no. 04-006, http://www.cms.hhs.gov/smdl/ downloads/smd090904.pdf (accessed 1 February 2008).
    • CMS, Center for Medicaid and State Operations, "Guidance for States on Preferred Drug Lists (PDLs) and Prior Authorization," State Medicaid Director Letter, 9 September 2004, SMDL no. 04-006, http://www.cms.hhs.gov/smdl/ downloads/smd090904.pdf (accessed 1 February 2008).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.